Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Dealing

24 Apr 2018 17:04

RNS Number : 9918L
Omega Diagnostics Group PLC
24 April 2018
 

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

 

PDMR Dealing

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it was notified on 24 April 2018 that Edward Valente, Group R&D Director of the Company has purchased 124,044 ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") at a price of 14.5 pence per Ordinary Share.

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Edward Valente

2.

Reason for notification

b)

Position / status

Group R&D Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Purchase of Ordinary Shares

 GB00B1VCP282

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Volume(s)

Price(s) £

124,044

0.145

 

d)

Aggregated information

Aggregated volume Price

Aggregate Volume(s)

Volume weighted average Price) £

124,044

0.145

 

e)

Date of the transaction

24/04/18

f)

Place of the transaction

LSE

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Colin King, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

Jag Grewal, Group Sales and Marketing Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

 

Camille Gochez (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKQDKABKDBQB
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSTrading Update
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
2nd Dec 20197:00 amRNSInterim Results
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.